Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Lescol, Lamisil, Voltaren Emulgel mentioned as OTC switch candidates.

This article was originally published in The Tan Sheet

Executive Summary

NOVARTIS LESCOL LIPID LOWERER MAY BE OTC SWITCH CANDIDATE, Jerry Karabelas, Novartis Pharmaceuticals CEO and head of the company's healthcare operations, suggested at a review of the company's 1997 financial results held in London March 17. "Eventually, it is possible that the HMG-CoAs would convert over to OTC status," Karabelas said, in part because Lescol has "an ideal profile from a safety point of view." He did not specify in which countries an attempt to switch Lescol could be made.
Advertisement

Related Content

Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting

Topics

Advertisement
UsernamePublicRestriction

Register

PS088238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel